ANX did say in their latest PR they'd be resubmitting the 530 NDA in 4Q10. It makes sense for them to do so since the FDA only cited a manufacturing flaw. They have enough $$ from their latest financing in Jan10 to last them for the year. I think there is alot of short interest in the stock right now. When they issue another PR regarding the FDA, I think we'll see some life in the stock. Not to mention there is only a 10mil share float. I've been buying, small blocks, not really sure how much lower they can drop it.
That's how these bio pharms are, they get beaten down and then come back to life when news hits or as 'the' date approaches. I wouldn't be surprised if outta nowhere there's a PR regarding 514 with the FDA, even a pre meeting. that would really send us up. good luck
just look at SOMX
News 
Market Data 
Discover 
